Living with multiple myeloma means facing a complex and often aggressive form of cancer. For patients and their families, knowing how the disease might progress is vital for making informed decisions about care. New data suggests that looking at circulating tumor DNA (ctDNA) can provide a clearer picture of how the disease might behave.
Researchers analyzed data from 948 patients to see if these DNA fragments could predict outcomes. They found that higher levels of ctDNA were linked to a much higher risk of aggressive disease progression. Specifically, patients with these markers showed a significant decrease in overall survival. This link was also seen in specific groups, including patients whose cancer had already relapsed or become harder to treat.
While this finding shows that ctDNA is a potential predictor of survival, it is important to remember that this was not a clinical trial. It shows an association between the DNA markers and the outlook for the disease. Because the data is still being interpreted, talk to your doctor about how these markers might apply to your specific situation.
